Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11920156 Engineered natural killer (NK) cells and compositions and methods thereof

Patent 11920156 was granted and assigned to Indapta Therapeutics on March, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Indapta Therapeutics

0

Current Assignee

Indapta Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Guy Dipierro0

Date of Patent

March 5, 2024

0

Patent Application Number

164848130

Date Filed

February 8, 2018

0

Patent Citations

US Patent 7238526 Methods and cell line useful for production of recombinant adeno-associated viruses

0

US Patent 7241447 Adeno-associated virus vectors and uses thereof

0

US Patent 7537924 Virus strains

0

US Patent 7550296 Generation of replication competent viruses for therapeutic use

0

US Patent 7588767 Microorganisms for therapy

0

US Patent 7588771 Microorganisms for therapy

0

US Patent 7662627 Adeno-associated virus materials and methods

0

US Patent 7731952 Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response

0

...

Patent Primary Examiner

Michael Szperka

0

Patent abstract

The present invention provides engineered Natural Killer (NK) cells and methods of producing engineered NK cells. The engineered NK cells and compositions containing the engineered NK cells are useful for treating diseases such as cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11920156 Engineered natural killer (NK) cells and compositions and methods thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool